Literature DB >> 23211627

Faster, cheaper, safer, T-cell engineering.

Richard A Morgan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23211627      PMCID： PMC3521862          DOI： 10.1097/CJI.0b013e3182791257

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  9 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 3.  Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.

Authors:  Zsuzsanna Izsvák; Perry B Hackett; Laurence J N Cooper; Zoltán Ivics
Journal:  Bioessays       Date:  2010-09       Impact factor: 4.345

4.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

Review 5.  Transposons for gene therapy!

Authors:  Zoltán Ivics; Zsuzsanna Izsvák
Journal:  Curr Gene Ther       Date:  2006-10       Impact factor: 4.391

6.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

7.  Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.

Authors:  P D Peng; C J Cohen; S Yang; C Hsu; S Jones; Y Zhao; Z Zheng; S A Rosenberg; R A Morgan
Journal:  Gene Ther       Date:  2009-06-04       Impact factor: 5.250

Review 8.  A transposon and transposase system for human application.

Authors:  Perry B Hackett; David A Largaespada; Laurence J N Cooper
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

9.  A human memory T cell subset with stem cell-like properties.

Authors:  Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440
  9 in total
  2 in total

1.  PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.

Authors:  Masaya Suematsu; Shigeki Yagyu; Nobuyoshi Nagao; Susumu Kubota; Yuto Shimizu; Miyuki Tanaka; Yozo Nakazawa; Toshihiko Imamura
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

2.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.